AbbVie (ABBV) stock analysis and fair value
ABBV · NYSE · Healthcare
276,47 US$
▲ +1,49%
In 30 seconds
The business. Healthcare. Sells 61,2 B US$ a year, keeps 7% as profit and sales grow 6,0% a year (last 5 years).
Strength. Passes 4 of 8 quality checks, but debt weighs: 14,8 years of profit.
ABBV fair value
Work out what the stock is worth with your own growth, margin and return assumptions. Free during launch.
See the fair valueAbbVie key numbers
- Market cap
- 488,6 B US$
- P/E (price ÷ earnings)
- 117,1
- Dividend yield
- 2,41%
- Revenue growth
- 10,1%
- a year, over 9 years
- Profit margin
- 6,9%
- Quality checks
- 4/8
Fiscal 2025 financials, as filed with the SEC.
What analysts say
Buy
32 of 39 analysts recommend buying.
See everything about ABBV on Cerne
- Fair value with your own assumptions
- Every analyst and price target
- 10 years of financials in simple charts
- Dividends, earnings and ratios vs. the sector